Disclaimer: We may earn a commission if you make any purchase by clicking our links. Please see our detailed guide here.

Follow us on:

Birth Cord Cells Can Boost Survival of Critically ill Covid Patients

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

Join the Opinion Leaders Network

Join the Techgenyz Opinion Leaders Network today and become part of a vibrant community of change-makers. Together, we can create a brighter future by shaping opinions, driving conversations, and transforming ideas into reality.

Critically ill Covid-19 patients treated with non-altered stem cells from umbilical cord connective tissue were more than twice as likely to survive as those who did not have the treatment, according to a small study.

The clinical trial carried out at four hospitals in Jakarta, Indonesia, also showed that administering the treatment to Covid-19 patients with an added chronic health condition such as diabetes, hypertension or kidney disease increased their survival more than fourfold.

The findings were published in the STEM CELLS Translational Medicine. All 40 patients who took part in the double-blind, controlled, randomized study were adults in intensive care who had been intubated due to Covid-19-induced pneumonia.

Half were given intravenous infusions containing umbilical mesenchymal stromal cells or stem cells derived from the connective tissue of a human birth cord, and half were given infusions without them.

“The survival rate of those receiving the stem cells was 2.5 times higher and climbed even more — 4.5 times — in the Covid-19 patients who had other chronic health conditions,” said Ismail Hadisoebroto Diogo, Professor at Cipto Mangunkusumo Central Hospital-Universitas in Indonesia.

He said the stem cell infusion was also found to be safe and well-tolerated, with no life-threatening complications or acute allergic reactions in seven days of post-infusion monitoring.

Previous clinical trials have shown that treating Covid-19 pneumonia patients with stem cells from umbilical cord connective tissue may help them survive and recover more quickly. Still, the Indonesian study is the first to treat intubated, critically ill Covid-19 pneumonia patients with a naive or non-genetically manipulated, form of the stem cells.

“Unlike other studies, our trial used stem cells obtained through explants from actual umbilical cord tissue and we did not manipulate them to exclude ACE2, a cellular protein thought to be an entry point for Covid-19,” Dilogo said.

Some research suggests that one of the main causes of acute respiratory distress in Covid-19 patients is “cytokine storm,” a condition in which infection prompts the body’s immune system to flood the bloodstream with inflammatory proteins.

“Although our study focused on a small number of patients, we think this experimental treatment could potentially lead to an effective adjuvant therapy for Covid-19 patients in intensive care who do not respond to conventional supportive treatment,” Dilogo said.

Partner With Us

Digital advertising offers a way for your business to reach out and make much-needed connections with your audience in a meaningful way. Advertising on Techgenyz will help you build brand awareness, increase website traffic, generate qualified leads, and grow your business.

Join 10,000+ Fellow Readers

Get Techgenyz’s roundup delivered to your inbox curated with the most important for you that keeps you updated about the future tech, mobile, space, gaming, business and more.


Find Apps

The Ultimate Hub for Discovering Apps Unlock a world of apps: your ultimate hub for exploring and discovering limitless possibilities for on your every needs.

Power Your Business

Solutions you need to super charge your business and drive growth

More from this topic